Further federal and state proposals and healthcare reforms are likely, which could limit the prices that can be charged for the product candidates that we develop and may further limit our commercial opportunity… an executive order issued by the White House on May 12, 2025, directs the Department of Health and Human Services (HHS) to implement a “Most Favored Nation” drug pricing policy.
